Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Limited has achieved its first US sales revenue for its Remplir™ nerve repair product, marking a significant milestone in its commercialization strategy. The company transitioned from receiving US FDA clearance to revenue generation in just over three months, leveraging its network of specialist distributors and logistics partner Uniphar. This development is part of Orthocell’s strategic plan to build familiarity and knowledge among US surgeons, aiming for widespread adoption and revenue growth in the $1.6 billion US nerve repair market.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Its product portfolio includes collagen medical devices for tissue reconstruction and healing in dental and orthopedic applications. The company’s flagship products include Remplir™ for peripheral nerve reconstruction, Striate+™ for dental applications, and SmrtGraft™ for tendon repair. Orthocell is actively expanding its market presence and is engaged in technology transfer and regulatory processes in the US.
Average Trading Volume: 1,139,323
Technical Sentiment Signal: Buy
Current Market Cap: A$317.6M
See more insights into OCC stock on TipRanks’ Stock Analysis page.